Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 11/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3431236 | 0.84 | LMNA (0.42) | CHRNA7KCNH2LMNAADORA1ADORA2A | |
| SCHEMBL3430562 | 0.81 | CHRNA7 (0.56) | CHRNA7KCNH2DHFR | |
| SCHEMBL3433512 | 0.80 | CHRNB2 (0.51) | LMNA | |
| SCHEMBL4785217 | 0.80 | CHRNA7 (0.52) | CHRNA7KCNH2ADORA1ADORA2A | |
| SCHEMBL3432395 | 0.78 | MAP3K12 (0.52) | LMNA | |
| SCHEMBL4785225 | 0.72 | CHRNA7 (0.51) | CHRNA7KCNH2DHFR | |
| SCHEMBL30463625 | 0.72 | DHFR (0.56) | LMNAADORA1ADORA2ADHFR | |
| SCHEMBL4254231 | 0.71 | DHFR (0.46) | LMNAADORA1ADORA2ADHFR | |
| SCHEMBL19381894 | 0.68 | CHRNA7 (0.58) | CHRNA7KCNH2 | |
| SCHEMBL4560012 | 0.67 | DHFR (0.52) | LMNAADORA1ADORA2ADHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310340-A1 | METHOD OF TREATING MUSCULAR DEGRADATION | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| EP-2265607-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | Rigel Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009103032-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310340-A1 | METHOD OF TREATING MUSCULAR DEGRADATION | PYGM, CKMT1A; CKMT1B, SMN1; SMN2 | CHRNA7 1059/4885KCNH2 3958/4885LMNA 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.